Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRT5421 + MRT5424 + MRT5429
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MRT5421, MRT5424, and MRT5429 are experimental quadrivalent influenza vaccine (QIV) candidates based on messenger RNA (mRNA) technology. Developed by Sanofi (following the acquisition of Translate Bio), these candidates utilize lipid nanoparticle (LNP) delivery systems to encode hemagglutinin (HA) proteins from four influenza strains (typically two A strains and two B strains). They are being evaluated in Phase 1/2 clinical trials to determine the optimal formulation for safety and immunogenicity compared to standard-of-care inactivated or recombinant influenza vaccines. The program aims to leverage the rapid manufacturing and potentially enhanced immune response associated with mRNA platforms to address seasonal influenza.
- Other names
- Sanofi mRNA influenza vaccineTranslate Bio mRNA influenza vaccineQuadrivalent mRNA influenza vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on MRT5421 + MRT5424 + MRT5429.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRT5421 + MRT5424 + MRT5429.